A privately-held company developing
Proprietary drug transporter activating technology
For targeted and effective delivery of anticancer drugs

Molecular mimicry technology turning co-administered anti-cancer agents more efficacious, less toxic

Only a small fraction of the administered anti-cancer agent can make it into the tumor. The novel technology of DrugCendR turns the tumor microenvironment into a drug conduit, allowing efficient access of anti-cancer agents deep into the tumor. As a consequence, co-administered anti-cancer agents may become more tumor-targeted, leading to an improved efficacy, as well as an improved safety profile.

> Science

Molecular mimicry technology
image photo

The Challenge

Current medications fail to sufficiently penetrate solid tumors.

learn more >

image photo

Technology

Novel technology hijacks body’s own transport system to deliver anti-cancer drugs deep into the tumor.

learn more >

image photo

Key Publications

Clinical-stage molecular mimicry agent validated has been validated in more than 150 publications.

learn more >